Latham & Watkins Advises on Travere’s Upsized US$475 Million Convertible Senior Notes Offering

Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced the pricing of its underwritten offering of US$475 million aggregate principal amount of 0.50% convertible senior notes due 2032. The sale of the notes is expected to close on May 11, 2026, subject to customary closing conditions. The aggregate principal amount of the offering was increased from the previously announced offering size of US$400 million. Travere also granted the underwriters of the notes a 30‑day option to purchase up to an additional US$50 million aggregate principal amount of notes, solely to cover over‑allotments.

Latham & Watkins LLP represents the underwriters in the transaction with a Capital Markets team led by San Diego partner Matt Bush, New York/Los Angeles partner Greg Rodgers, Los Angeles partner Arash Aminian Baghai, and San Diego counsel Anthony Gostanian, with associates Andrew Bentz, Rachel Staub, Sterling Swift, and Katie Raya. Advice was also provided on tax matters by New York partner Bora Bozkurt, with associate Sam Yang.